Insights on Urology Care Costs, Prostate Cancer, and Screening Methods

raymond paul blanc md amhe 2010 ch teau n.w
1 / 42
Embed
Share

Exploring the dynamics of urology care costs, prevalence and impact of prostate cancer, and the effectiveness of screening methods. Discover the interplay between socioeconomic factors, education burdens, and healthcare outcomes in this insightful narrative. Dive into the nuances of prostate cancer management, risk assessment formulas, and the debate surrounding PSA screening. Uncover key statistics, research findings, and emerging trends in the field of urology for the benefit of mankind.

  • Urology Care
  • Prostate Cancer
  • Screening Methods
  • Healthcare Outcomes
  • Cancer Management

Uploaded on | 0 Views


Download Presentation

Please find below an Image/Link to download the presentation.

The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author. If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.

You are allowed to download the files provided on this website for personal or commercial use, subject to the condition that they are used lawfully. All files are the property of their respective owners.

The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.

E N D

Presentation Transcript


  1. Raymond Paul-Blanc, MD AMHE 2010 Ch teau Montebello, Qu bec, Canada

  2. The greater the ignorance the greater the dogmatism. -Sir William Osler

  3. -Dynamic state that includes Advancement Improvement Adoption of New Methods and Insights Purpose: Benefit of Mankind

  4. A) Socioeconomics B) Education burden from patient (cultural, emotional) C)Education burden from provider( persistence of old habits and limited or absence of esprit critique )

  5. NIH (2007) Reports Urology Care costs $11 Billion UTIs 3.5 B Kidney stones 2.1 B Prostate Cancer 1.3 B Bladder Cancer 1.1 B Kidney Cancer 401 M BPH 84 M ED 328 M Interstitial Cystitis 66M

  6. 1) PROSTATE CANCER 2) ERECTILE DYSFUNCTION 3) TESTOSTERONE REPLACEMENT 4) EJACULATORY DISORDERS

  7. 192,000 new cases (NIH,2009) 23,000 deaths , decreasing from 30,000 in the 1980s (NIH, 2009) Impact of nutrition: fat, soy, pomegranate, herbs, exercise Impact of chemoprevention finasteride PCPT study (2006) dutasteride REDUCE study (2009)

  8. DRE+PSA+PCA-3 NIH Mathematical Formula -Age -Race -Family Hx- -PSA -DRE -Prior prostate biopsy

  9. DRE +PSA as screening vs control group F/U 7-10 yrs mortality from prostate cancer not different from case control. 50 deaths vs. 40 deaths.

  10. 182,000 men started in 1999-2009 PSA screening only vs. case control Conclusion: Mortality decreased by 20 % with risk of overdiagnosis

  11. PSA: ( Free/Total) PSA Velocity PSA Density PCA-3 (urine) Crawford- Colorado EPCA-2 ( serum)(Partin-Hopkins) DOGS Detection of VOC (Volatile organic compound) (Cornu, Paris 2009) 66 pts Sens 100%, spec 96%

  12. Complimentary Alternative Medicine for Prostate Cancer Low-Risk Prostate Cancer Patients Weight reduction (aerobic) Low fat diet Fresh vegetables Fish oils 2-4 cups of green tea Vitamin E Selenium Lycopene Soy supplementation Vitamin D Fish Oil Pills

  13. Raised BMI index is associated with increase in cancers, heart diseases, DM, and deaths Prostate Cancer higher BMIs have: Diagnosed with lower PSAs Higher positive margins Have independent higher reoccurrence

  14. 50,ooo men at Harvard School of Public Health suggested that vitamin D may reduce the risk of all cancers by at least 30 % - Giovannucci. J Natl Cancer Inst. 2006 Apr 5:98 (7): 428 Increased cancer mortality associated with decreased sunlight.- including the following cancers: breast, colon, cancer, prostate, bladder, esophagus, kidney, lung, pancreas, rectum, stomach, non- Hodgkin s Lymphoma - Grant. Cancer. 2002; 94 (6):1867

  15. Vitamin D deficiency may underlie the major Risk factors for prostate cancer (rage, black race, and northern climate) Prostate cancer in the US are inversely related with ultraviolet radiation . Schwartz, GG, Hulka BS. Anticancer Res. 1990 Sept- Oct ; 10 (5A) : 1307-11

  16. Pomegranate and Prostate Cancer

  17. 69-75% growth inhabitation of PC3 Delayed progression into S phase Low levels of apoptosis In vivo studies in SCID mice show : 52% growth inhibition of LAPC-9 tumors 70% reduction in PSA Prolonged survival -A. Katz, Columbia University 2010

  18. Genistein and Daidzein are active metabolites -Genistein has shown to reduced DNA synthesis in LNCaP cells and inhibit the effect of testosterone in development of CaP in rats (Geller et al. Prostate, 34:75, 1998) A reduction of prostate cancer is associated with consumption of soy milk in the Adventist Health Study 1997

  19. Chick peas, soy, navy beans, lentils Legumes Intake should include 20-50 mg /day in Asian, African, and Mediterranean diets 1-3 mg/day in Western Diets

  20. Criteria: Low grade disease -PSA <10 PSA density <0.15 Gleason Score 6 <2/3 cores No more than 50 % involvement in each core Should repeat prostate biopsy in 1 year

  21. http://www.haiti-vacations.com/wp-content/uploads/2010/02/Saut-Mathurine-1024x768.jpghttp://www.haiti-vacations.com/wp-content/uploads/2010/02/Saut-Mathurine-1024x768.jpg

  22. Robotic Open XRT Brachytherapy Cryoablation HIFU? Outcome at 5 years similar

  23. Robotics: costs 2.3 million per machine, needs 150 cases per year for surgical expertise Will need 250 robotic cases to pay for machine No large difference in outcome when compared to open prostatectomy

  24. -Partin Table PSA-Gleason -Low Testosterone -Obesity -Diabetes (Co-factor) -Smoking -Economical Status

  25. Natl Health and Social Life Survey (2008) total 1410 men (18-59 yrs old) PE- 31 % ED-10% Results show increase in anxiety, distress, interpersonal difficulty, and loss of sexual satisfaction

  26. A) PDE-5 inhibitors- Viagra, Cialis, Levitra B) SSRI Prozac, Zoloft C) Combination of above D) Topical Aerosol (Lidocaine, Prilocaine)

  27. File:Haiti deforestation.jpg

  28. Whats New in Erectile Dysfunction? Mayo Clinic Proceedings: 40-49 year old men with E.D. twice as likely to develop E.D. Endothelial Disease Coronary Artery 3mm Penile Artery 1mm

  29. Desire Libido (testosterone) Erection Quality (sustainability/rigidity) Ejaculation (timely/powerful) testosterone Partner Satisfaction

  30. Loss of N.E. related to: Testosterone Sleeping Disorders Surgery Atherosclerosis

  31. Flaccid Penis: O2 tension 25-40 mm Hg Erect Penis: O2 tension 90-100 mm Hg Free O2: Nitric Oxide Synthesis (NO) NO + Guanylate Cyclase GTP to GMP (active vasodilatation) Lack of O2: Collagen Formation Fibrosis Restoring N.E. = Restoring O2 Restoring Erection

  32. V.E.D. : daily 5-10 minutes. Increases girth/length? Low-Dose PDE5 H/S (Viagra, Cialis, Levitra, etc.) Self-Injection Program(3 P s Solution) Topical Application (MUSE- Prostagladin)

  33. Provider more aware of T.D. 25% Depression 25% Diabetes Natural Decline (Andropause)

  34. Huggins and Hodges-1941- 2 Articles Conclusion: Testosterone administration caused and enhanced growth of Prostate Cancer. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941. Huggins C, Hodges CV.

  35. 31 patients who received TRT after Brachytherapy all maintained a PSA less than 1.0 ng/mL with a median follow-up of 5 years. Meta-Analysis from eighteen prospective studies involving 3,886 men with prostate cancer and 6,438 controls showed no association between circulating levels of testosterone and estrogen and incidence of prostate cancer. JNCI 2/2008

  36. Study involved 272 patients with prostate cancer who underwent radical prostatectomy, 49 patients who were found to have a testosterone less than 300 ng/dl did worse than patients with normal testosterone. ( Euro Urology 9/07) Testosterone and PSA-PSA did not rise above baseline during the testosterone flare in men with metastatic prostate cancer treated with LH-RH agonists. (NJM 1989; JU 2001). In hypogondal men . TRT results in only modest results in prostate size, approximately 15% for PSA and prostate volume increasing to match eugonadal men. But rising no higher. (NJM 2004)

  37. Low Testosterone and Prostate Cancer Possible Increased Risk Possible Higher Grade Disease Possible Higher-Stage at Presentation Possible Worse Prognosis (Jama 2006; J. Urol 200; AJ Clin 1997)

  38. The current data with TRT following prostate cancer treatment is changing; further data will provide clarity and will hopefully lead to new guidelines. Raymond Paul-Blanc, M.D.

Related


More Related Content